Scroll

darifenacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
muscarinic receptors antagonists	784	133099-04-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: enablex darifenacin darifenacin hydrobromide emselex	a competitive muscarinic receptor antagonist with greater affinity for the M3 receptor than for the other known muscarinic receptors, M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function Molecular weight: 426.56 Formula: C28H30N2O2 CLOGP: 4.28 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 55.56 ALOGS: -6.16 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

enablex
darifenacin
darifenacin hydrobromide
emselex

a competitive muscarinic receptor antagonist with greater affinity for the M3 receptor than for the other known muscarinic receptors, M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function

Molecular weight: 426.56
Formula: C28H30N2O2
CLOGP: 4.28
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 55.56
ALOGS: -6.16
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
7.50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	12.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.41 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	17 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 22, 2004	EMA	Merus Labs Luxco S.a R.L.
Dec. 22, 2004	FDA	WARNER CHILCOTT LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumonia viral	489.77	38.96	107	2955	6727	50595335
Soft tissue disorder	381.19	38.96	80	2982	4134	50597928
Herpes zoster	344.95	38.96	137	2925	70649	50531413
Fibromyalgia	239.49	38.96	93	2969	44885	50557177
Liver function test abnormal	230.11	38.96	90	2972	44249	50557813
Blood cholesterol increased	227.75	38.96	95	2967	55120	50546942
Oral pain	212.25	38.96	73	2989	24960	50577102
Leukopenia	206.18	38.96	94	2968	67434	50534628
Asphyxia	191.97	38.96	48	3014	5379	50596683
Peripheral swelling	187.22	38.96	129	2933	205807	50396255
Arthritis	183.79	38.96	94	2968	86627	50515435
Synovitis	181.24	38.96	105	2957	123760	50478302
Arteriosclerosis coronary artery	166.44	38.96	46	3016	7590	50594472
Infection	106.55	38.96	86	2976	172868	50429194
Anaemia	102.45	38.96	99	2963	252357	50349705
Joint swelling	99.16	38.96	96	2966	245190	50356872
Tenderness	79.84	38.96	33	3029	18532	50583530
Therapeutic product effect incomplete	70.36	38.96	52	3010	91463	50510599
Drug ineffective	46.98	38.96	131	2931	819202	49782860
Soft tissue swelling	46.58	38.96	11	3051	965	50601097

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumonia viral	328.96	39.78	73	2418	7749	64488492
Soft tissue disorder	231.69	39.78	47	2444	3229	64493012
Herpes zoster	192.01	39.78	82	2409	79105	64417136
Asphyxia	191.34	39.78	49	2442	9517	64486724
Fibromyalgia	160.86	39.78	58	2433	35673	64460568
Arteriosclerosis coronary artery	154.65	39.78	46	2445	15483	64480758
Blood cholesterol increased	141.83	39.78	58	2433	50008	64446233
Synovitis	132.33	39.78	68	2423	99022	64397219
Oral pain	117.57	39.78	43	2448	27450	64468791
Liver function test abnormal	116.23	39.78	53	2438	59348	64436893
Peripheral swelling	112.56	39.78	80	2411	209073	64287168
Arthritis	110.32	39.78	57	2434	83757	64412484
Leukopenia	97.52	39.78	56	2435	101186	64395055
Therapeutic product effect incomplete	78.22	39.78	49	2442	103433	64392808
Tenderness	77.64	39.78	29	2462	19573	64476668
Joint swelling	67.41	39.78	60	2431	215322	64280919
Infection	60.81	39.78	53	2438	184827	64311414
Anaemia	47.10	39.78	65	2426	378615	64117626
Arthralgia	46.39	39.78	70	2421	442190	64054051
Soft tissue swelling	44.66	39.78	10	2481	1092	64495149

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G04BD10	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence
FDA MoA	N0000000125	Cholinergic Muscarinic Antagonists
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D064804	Urological Agents
FDA EPC	N0000175700	Cholinergic Muscarinic Antagonist
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:53784	antispasmodics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Urgent desire to urinate	indication	75088002
Urge incontinence of urine	indication	87557004
Bladder muscle dysfunction - overactive	indication	236633002
Increased Urinary Frequency	indication
Angioedema	contraindication	41291007	DOID:1558
Hepatic failure	contraindication	59927004
Ulcerative colitis	contraindication	64766004	DOID:8577
Myasthenia gravis	contraindication	91637004	DOID:437
Gastrointestinal obstruction	contraindication	126765001
Acute constipation	contraindication	197119006
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Retention of urine	contraindication	267064002
Gastric retention	contraindication	307227006
Angle-closure glaucoma	contraindication	392291006	DOID:13550

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.6	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Kd	9.52	CHEMBL	CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		IC50	6.50	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	7.21	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		IC50	4.60	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	8.30	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	7.60	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.64	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	8.10	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Ki	7.20	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR		ACM3_RAT		Ki	8.60	CHEMBL

External reference:

ID	Source
D01699	KEGG_DRUG
133099-07-7	SECONDARY_CAS_RN
136198	RXNORM
4024903	VANDF
C0529351	UMLSCUI
CHEBI:391960	CHEBI
CHEMBL1346	ChEMBL_ID
CHEMBL1200935	ChEMBL_ID
DB00496	DRUGBANK_ID
C101207	MESH_SUPPLEMENTAL_RECORD_UI
444031	PUBCHEM_CID
321	IUPHAR_LIGAND_ID
7153	INN_ID
APG9819VLM	UNII
19114	MMSL
64038	MMSL
d05422	MMSL
008802	NDDF
008812	NDDF
416140008	SNOMEDCT_US
416385001	SNOMEDCT_US
426766002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-202	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	25 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-202	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	25 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-203	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	25 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-203	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	25 sections
Darifenacin	Human Prescription Drug Label	1	16571-767	TABLET, FILM COATED, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	16571-768	TABLET, FILM COATED, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	33342-276	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	33342-277	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
DARIFENACIN	Human Prescription Drug Label	1	46708-223	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
DARIFENACIN	Human Prescription Drug Label	1	46708-224	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	52605-067	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	52605-068	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
Enablex	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5363	TABLET, EXTENDED RELEASE	15 mg	ORAL	NDA	25 sections
Enablex	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5704	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	NDA	25 sections
DARIFENACIN	Human Prescription Drug Label	1	62332-223	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
DARIFENACIN	Human Prescription Drug Label	1	62332-224	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	65862-861	TABLET, FILM COATED, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	65862-862	TABLET, FILM COATED, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	69097-431	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	24 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	69097-432	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	24 sections
Darifenacin 7.5 mg	HUMAN PRESCRIPTION DRUG LABEL	1	70700-182	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	25 sections
Darifenacin 15 mg	HUMAN PRESCRIPTION DRUG LABEL	1	70700-183	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	25 sections
darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	70754-161	TABLET, FILM COATED, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	28 sections
darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	70754-162	TABLET, FILM COATED, EXTENDED RELEASE	15 mg	ORAL	ANDA	28 sections
Darifenacin 7.5 mg	HUMAN PRESCRIPTION DRUG LABEL	1	71205-900	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	25 sections
Darifenacin 7.5 mg	HUMAN PRESCRIPTION DRUG LABEL	1	71205-900	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	25 sections
Darifenacin 15 mg	HUMAN PRESCRIPTION DRUG LABEL	1	71205-901	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	25 sections
Darifenacin 15 mg	HUMAN PRESCRIPTION DRUG LABEL	1	71205-901	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	25 sections